New immune drug shows promise in early cancer trial
NCT ID NCT03336606
First seen May 22, 2026 · Last updated May 22, 2026
Summary
This early-phase trial tested a drug called MEDI0562, which aims to boost the immune system's ability to fight cancer. It was given to 13 patients with advanced head and neck cancer or melanoma before their surgery. The main goal was to see if the drug safely activates the immune system, not to cure the disease. Participants needed to be healthy enough for surgery and had to stop other cancer treatments beforehand.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.